New study finds evidence to show that the commonly used antimalarial drug, dihydroartemisinin-piperaquine, is failing to treat patients in some regions of Cambodia.

The World Malaria Report 2015, launched today, focuses on the great strides made against malaria across the world and looks at the challenges that lie ahead for malaria endemic countries.

WWARN and CDISC are working in partnership to develop the first malaria clinical data standard which will facilitate alignment of electronic acquisition, exchange, submission and archiving of clinical malaria data collection.

The new Antiretroviral PK/PD Study Group is pooling data on malaria and HIV co-infections to understand the effects of both antiretrovirals and HIV disease on a patient’s drug exposure to lumefantrine.

The global fight against antimicrobial resistance could be under threat unless the evidence base for policies to control resistance is radically improved, according to a major new series of papers published in The Lancet.

The Parasite Clearance Study Group has provided valuable baseline data on parasite clearance and information on the factors that influence the rate at which malaria parasites are eliminated from a patient’s system.

Research from WWARN’s Head of Medicine Quality suggests that improved guidelines are needed to prevent the use of poor quality medicines in clinical trials.

A new collaborative study is investigating the safety, tolerability and efficacy of two Triple Artemisinin-based Combination Therapies (TACTs) to help prolong the lifespan of the important ACTs in the face of increasing artemisinin and partner drug resistance.

Find out about WWARN and partner sessions at the 64th ASTMH Annual Meeting.

Many colleagues will remember Dr Alan Magill, Director of Global Health at the Bill & Melinda Gates Foundation. Alan died suddenly and unexpectedly on 19 September in Seattle.

WWARN’s new Low-dose Primaquine Efficacy and Safety Study Groups are investigating both the safety and efficacy profiles of the antimalarial treatment, primaquine, to stop the transmission of falciparum malaria. Find out how you can get involved.

Will you be attending this year’s American Society of Tropical Medicine and Hygiene 64th Annual Meeting? The WWARN team hopes to catch up with you to exchange ideas on how we might work together.

WWARN researchers have worked together with experts at Global Good-Intellectual Ventures Laboratory and the Queensland University of Technnology to produce a new tool designed to support researchers using microscopy in malaria research.

Recently the WWARN Pharmacology group and partners, published a study in the journal, Antimicrobial Agents and Chemotherapy. The study used PK/PD models to explore ways to enhance the efficacy of the commonly used antimalarial, artemether-lumefantrine (AL), in pregnant women and reduce the risk of t...

Pooled analysis identifies lumefantrine concentrations needed for curing malaria patients at highest risk

A new study from WWARN’s ACT Africa Baseline Study Group finds that current indicators of the efficacy of ACT based on persistence of parasites in the first 3 days after treatment may need some adjustment for African populations, due to the differences in immunity between African and Asian populati...

New report launched today by the WHO summarizes the remarkable progress seen, on a global and regional level, in reversing malaria mortality and incidence since 2000.

WWARN Scientific Director reviews new study published in the Proceedings of the National Academy of Sciences.

The WorldWide Antimalarial Resistance Network (WWARN) has been shortlisted for the 2015 Times Higher Education (THE) Award for the ‘International Collaboration of the Year’.

The 193 Member States of the United Nations have reached agreement on the outcome document that will constitute the new sustainable development agenda that will be adopted this September by world leaders.